BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 38525896)

  • 1. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis.
    Yao J; Huang W; Gao L; Liu Y; Zhang Q; He J; Zhang L
    PLoS One; 2024; 19(6):e0304283. PubMed ID: 38848379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.
    Pichi F; Abdi A; Aljneibi S; El Ghrably I; Agarwal A; Ghazi NG
    Int Ophthalmol; 2024 Jun; 44(1):275. PubMed ID: 38916818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual outcomes following anti-VEGF therapy in patients with DME.
    Panigrahi PK; Patro M
    Indian J Ophthalmol; 2024 Jul; 72(Suppl 4):S718. PubMed ID: 38953138
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network.
    Jampol LM; Glassman AR; Bressler NM
    JAMA Ophthalmol; 2015 Sep; 133(9):983-4. PubMed ID: 26087135
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment Effects of Switching to Faricimab in Eyes with Diabetic Macular Edema Refractory to Aflibercept.
    Tatsumi T; Kaiho T; Iwase T; Miura G; Shimizu D; Niizawa T; Ozawa Y; Arai M; Oshitari T; Takatsuna Y; Baba T
    Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792915
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema.
    Payne CJ; Gupta U; Maatouk CM; Kuo BL; Perkins SW; Singh RP; Talcott KE
    Eye (Lond); 2024 Jun; 38(9):1687-1693. PubMed ID: 38448732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema.
    Saima Y; Yokota H; Kushiyama A; Hanaguri J; Ohno A; Takase K; Sugiyama R; Muranaka K; Yamagami S; Nagaoka T
    Sci Rep; 2024 Jun; 14(1):13798. PubMed ID: 38877041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient regression of new vessels after anti-vascular endothelial growth factor monotherapy in proliferative diabetic retinopathy.
    Venkatesh R; Anilkumar A; Mangla R; Sharief S; Chhablani J
    Clin Exp Optom; 2024 Jul; 107(5):587-588. PubMed ID: 37078163
    [No Abstract]   [Full Text] [Related]  

  • 10. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
    Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
    Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
    [No Abstract]   [Full Text] [Related]  

  • 11. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.
    Lindboe JB; Brynskov T; Sørensen TL; Schmidt Laugesen C
    Acta Ophthalmol; 2024 Jun; 102(4):e661-e662. PubMed ID: 38525896
    [No Abstract]   [Full Text] [Related]  

  • 13. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
    Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
    Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
    Parca O; Cetin EN
    Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.